Cargando…
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
BACKGROUND: Interleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4(+) and CD8(+) T cells, and regulatory T cells (T(regs)). Low concentrations of IL-2 induce signaling through the h...
Autores principales: | Lopes, Jared E, Fisher, Jan L, Flick, Heather L, Wang, Chunhua, Sun, Lei, Ernstoff, Marc S, Alvarez, Juan C, Losey, Heather C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204809/ https://www.ncbi.nlm.nih.gov/pubmed/32317293 http://dx.doi.org/10.1136/jitc-2020-000673 |
Ejemplares similares
-
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021) -
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells
por: LaPorte, Kathryn M, et al.
Publicado: (2023) -
Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020) -
Implication of (99m)Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
por: Gao, Yu, et al.
Publicado: (2023) -
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)